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Aims To investigate the safety and potential efficacy of the novel non-steroidal mineralocorticoid receptor antagonist
finerenone in patients with worsening chronic heart failure and reduced left ventricular ejection fraction (HFrEF) and
at high risk of hyperkalaemia and worsening renal dysfunction.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
The MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF; NCT01807221) is a multi-
centre, randomized, double-blind, active-comparator-controlled, six-parallel-group, phase 2b dose-finding study. In
total, 1060 patients with HFrEF and concomitant type 2 diabetes mellitus and/or chronic kidney disease (CKD) will
be randomized within 7 days of emergency presentation to hospital for worsening chronic HF to receive finerenone
(one of five doses in the range 2.5–20.0mg once daily) or eplerenone (25mg every second day to 50mg once daily
for 90 days). The primary objective is to investigate the safety and potential efficacy (measured as the percentage
of individuals with a decrease in plasma N-terminal pro-B-type natriuretic peptide [NT-proBNP] of more than 30%
relative to baseline at day 90± 2) of different oral doses of finerenone compared with eplerenone. Other objectives
are to assess the effects of finerenone on a composite clinical endpoint (death from any cause, cardiovascular
hospitalizations, or emergency presentations for worsening chronic HF), and on changes in health-related quality of
life from baseline.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusions ARTS-HF is the first phase 2b clinical trial to investigate the effects of finerenone on plasma NT-proBNP in a high-risk
population of patients who have worsening chronic HF with type 2 diabetes mellitus and/or CKD presenting at the
emergency department.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Antagonist • Chronic kidney disease • Heart failure • Mineralocorticoid receptor • Type 2
diabetes mellitus
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Introduction
The steroidal mineralocorticoid-receptor antagonists (MRAs)
spironolactone and eplerenone reduce mortality and hospitaliza-
tions for heart failure (HF) in patients with HF and a reduced
ejection fraction (HFrEF)1,2 and are a class 1A recommenda-
tion for the treatment of this patient population in international
guidelines.3–5 However, steroidal MRAs significantly increase the
risk of hyperkalaemia and worsening renal function.6,7 Thus, they
are still underused and often discontinued once administered.8
This is particularly the case in patients already at high risk of hyper-
kalaemia, including those with type 2 diabetes mellitus (T2DM)
and chronic kidney disease (CKD), who, at best, can usually
tolerate treatment with only a low dose of an MRA in combination
with an angiotensin-converting enzyme (ACE) inhibitor and/or an
angiotensin receptor blocker (ARB).
Patients with worsening chronic HFrEF who require hospitaliza-
tion or intensified ambulatory treatment have a very increased risk
of post-discharge mortality and hospital readmission, with rates
as high as 15% and 30%, respectively, within 60–90 days.9–12 The
high morbidity and mortality in patients with worsening chronic
HF represent an unmet need in the treatment of these patients.
As aldosterone levels are elevated in HF, the mineralocorticoid
receptor (MR) may be an important therapeutic target in patients
with worsening HFrEF.4 However, because the prevalence of CKD
and/or T2DM is high in patients hospitalized for worsening chronic
HFrEF,13,14 the risk of hyperkalaemia and worsening renal function
may also be high if they were to be treated with currently avail-
able MRAs, especially early during their hospital stay when renal
function may be fluctuating. There is therefore a need for a new
MRA that, like the currently available steroidal MRAs,7,15 is able
to improve cardiovascular outcomes, but is less likely to induce
hyperkalaemia in patients with worsening chronic HFrEF and con-
comitant T2DM and/or CKD.
Finerenone (BAY 94–8862) is a next-generation, oral, selective,
non-steroidal MRA. In recent preclinical rat studies, chronic
finerenone treatment prevented the development of functional
and structural heart and kidney damage more efficiently than the
steroidal MRA eplerenone, when comparing equinatriuretic doses.
14C-finerenone distributes equally to the heart and kidney,16 in
contrast to eplerenone, which demonstrates at least a threefold
greater accumulation in the kidney than in the heart of con-
scious rats.17 Finerenone combines spironolactone’s potency
with eplerenone’s selectivity and, based on its non-steroidal
chemical structure,18 it may have an improved cardiac vs. renal
activity ratio (relative renal sparing) because of a combination
of physicochemical properties that influence plasma transport
and tissue penetration and differential affinity of the MR–drug
complex for tissue-specific cofactors. Therefore, finerenone may
offer end-organ protection with a reduced risk of electrolyte dis-
turbances (and therefore hyperkalaemia) compared with steroidal
MRAs.16
Finerenone has been previously studied in 392 patients
with stable HFrEF and mild to moderate CKD (estimated
glomerular filtration rate [eGFR] 60 to <90mL/min.1.73m2
and 30–60mL/min.1.73m2, respectively). In the phase 2a ..
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.. MinerAlocorticoid Receptor Antagonist Tolerability Study (ARTS;
NCT01345656), finerenone 5.0–10.0mg/day reduced plasma
natriuretic peptides levels and albuminuria to at least the same
magnitude as spironolactone 25–50mg/day, but was associated
with a significantly smaller mean increase in serum potassium
concentration ([K+]) and smaller decreases in eGFR.19
In patients with worsening chronic HF, baseline serum levels
and the magnitude of change in the concentration of natriuretic
peptides are known to provide incremental prognostic value,20–22
and thus represent predictors of adverse outcomes.20–24 Against
this background, ARTS-Heart Failure (ARTS-HF) is a dose-finding
study designed to investigate the effects of 90 days of finerenone
(dose range, 2.5–20mg/day) or eplerenone (dose range, 25mg
every other day to 50mg/day) on plasma N-terminal pro-B-type
natriuretic peptide (NT-proBNP) concentrations in high-risk
patients with worsening chronic HFrEF and concomitant T2DM
and/or CKD.
Methods
Study design
ARTS-HF (ClinicalTrials.gov identifier: NCT01807221) is a multi-
centre, randomized, double-blind, active-comparator-controlled,
six-parallel-group, phase 2b dose-finding study. Patients with worsen-
ing chronic HFrEF who also have T2DM with CKD, T2DM without
CKD, or moderate CKD alone will receive finerenone at a dose of
2.5–20.0mg once daily or eplerenone at a dose of 25mg every second
day, 25mg once daily, or 50mg once daily.
It is intended that 1510 patients will be screened and 1060 will
receive treatment with study drug.
Objectives
The primary objective of the study is to investigate the safety and
potential efficacy (measured as the percentage of individuals with a
decrease in plasma NT-proBNP of more than 30% relative to baseline
at visit 9 [day 90± 2]) of different oral doses of finerenone given once
daily.
Further exploratory objectives are to assess:
• effects on a composite endpoint of death from any cause, cardio-
vascular hospitalizations, or emergency presentations for worsen-
ing HFrEF until visit 9
• effects on plasma B-type natriuretic peptide (BNP) and
NT-proBNP at visit 5 (day 30± 2), visit 7 (day 60± 2), and visit
9 (with decreases or increases in laboratory results monitored
continually throughout the trial)
• effects on other efficacy biomarkers (galectin 3 and N-terminal
procollagen III propeptide) at baseline, visits 5, 7 and 9, and
follow-up
• effects on safety (troponin T and cystatin C) biomarkers at baseline,
visits 5, 7 and 9, and follow-up, on vital signs at baseline, visits 3, 4,
5, 7 and 9, and follow-up, on laboratory safety results at every visit,
including on serum K+, creatinine levels and eGFR, and on adverse
events at every visit, including on the predefined adverse events of
special safety interest i.e. (an increase in blood [K+] ≥5.6mmol/L
leading to discontinuation or emergency presentation of worsening
chronic HF after the start of study drug treatment)
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• change in health-related quality of life (HRQoL) from baseline
to visit 5 and visit 9 using the Kansas City Cardiomyopathy
Questionnaire and EuroQoL Group five-dimension, three-level
questionnaire.
Blinded adjudication of all hospitalizations and deaths will be per-
formed by a central committee.
Patients
Adults with worsening chronic HFrEF requiring emergency presenta-
tion to hospital and treatment with intravenous diuretics, who meet all
of the inclusion criteria and none of the exclusion criteria (Table 1), are
eligible for the treatment phase of the study. Briefly, patients must have
T2DM and/or CKD, have been treated with evidence-based therapy for
HF for at least 3months before emergency presentation to hospital,
and have a medical history of a left ventricular EF of 40% or less within
the last 12months. Patients with acute de novo HF or acute inflamma-
tory heart disease, acute coronary syndromes in the last 30 days before
the screening visit, cardiogenic shock or valvular heart disease requir-
ing surgical intervention, those with a left ventricular assist device or
awaiting heart transplantation, and patients who have experienced a
stroke or transient ischaemic attack within 3months before screening
will not be eligible for participation.
It should be noted that, although atrial fibrillation (AF) is not an
exclusion criterion, the number of patients with AF documented from
initial emergency presentation to hospital up to randomization will
be controlled within the study. The proportion of patients with AF
enrolled in the study will be limited to no more than 45% of the planned
total number of randomized patients at the end of the study.
Study medication
Initially, patients were randomized 1:1:1 in the 7-day period follow-
ing emergency presentation to hospital to receive finerenone oral,
immediate-release tablets once daily at a dose of 2.5mg or 5.0mg, or
oral eplerenone every second day at a dose of 25mg. Once approx-
imately 300 patients were randomized, the safety and tolerability (in
particular, changes in serum [K+] compared with baseline, the num-
ber of patients with hyperkalaemia [[K+] ≥5.6mmol/L], the number of
patients with a decrease in eGFR of ≥30%, and the incidence of adverse
events related to worsening renal function) of the initial doses were
assessed by an independent Data and Safety Monitoring Board (DSMB)
in January 2014. Based on this safety and tolerability assessment, the
DSMB decided that the following pre-planned treatment arms could be
introduced into the study: finerenone 7.5mg, uptitrated to 15.0mg at
visit 5 (day 30± 2); finerenone 10.0mg, uptitrated to 20.0mg at visit 5;
finerenone 15.0mg, uptitrated to 20.0mg at visit 5 (Figure 1). Random-
ization was accordingly adapted to obtain approximately equal sample
sizes across all finerenone treatment groups and a randomization ratio
of 1:1.5 between each finerenone treatment group and the eplerenone
treatment group by the end of the study. The randomization was strat-
ified by region, comorbidities (CKD, T2DM, or both) and MRA use at
emergency presentation to hospital [MRA naïve (no use of an MRA in
the 5 days before emergency presentation) or previous MRA use (use
of an MRA in the 5 days prior to emergency presentation)].
Patients will begin treatment with finerenone or eplerenone in
addition to their standard therapy for HF and will receive the doses
described above throughout the acute/vulnerable phase (days 1–30).
Provided that serum/plasma [K+] is 5.0mmol/L or less in the locally ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. analysed sample at visit 5 (day 30± 2), study drug will be uptitrated
according to the schedule in Figure 1.
During the chronic phase (days 31–90), there will be another
up-titration (eplerenone group) or sham up-titration (finerenone
group) depending on the [K+] in the locally analysed sample at visit
7 (day 60± 2), according to the schedule in Figure 1.
Serum/plasma potassium monitoring
Patients will maintain their normal diet throughout the study and
will not be given any specific advice on dietary sodium or potassium
restrictions. If a patient undergoes a change in clinical status that is
known to influence serum/plasma electrolyte levels or fluid balance
(e.g. vomiting and/or diarrhoea for >1 day), it is recommended that
serum/plasma [K+] is reassessed as soon as possible after the acute
event. Any reassessment of serum/plasma [K+] must be analysed
locally and centrally. At each scheduled visit, blood samples will be
collected for measurement of parameters including serum/plasma [K+].
Investigators should stop the study drug permanently in the event of a
confirmed [K+] of 5.6mmol/L or more. Such a discontinuation must be
reported within 24 h as a serious adverse event. A summary of blood
potassium monitoring is given in Figure 2.
Investigations
Patients will be assessed at the screening visit, at baseline/day 1 (start of
drug administrations), and according to the schedule shown in Table 2.
A follow-up visit will be scheduled 30± 5 days after the last intake of
study medication. Patients who discontinue the study prematurely will
also be assessed as soon as possible after discontinuation.
Details of the assessments made at each visit are shown in Table 2
and summarized in the Supporting Information, Figure S1. Safety (tro-
ponin T and cystatin C) and efficacy (plasma BNP, NT-proBNP, galectin
3, and N-terminal procollagen III propeptide, biomarkers will be mea-
sured at baseline, at visits 5, 7 and 9 and at follow-up. Serum [K+],
serum creatinine concentration, and eGFR will be measured at each
visit. Furthermore, any changes (i.e. decreases or increases) in labora-
tory results will be monitored continually throughout the trial.
Adverse events monitoring
Monitoring in ARTS-HF is coordinated by an independent DSMB,
comprising cardiologists, endocrinologists and nephrologists, as well
as a biostatistician (DSMB members are listed in the Suppporting
Information, Appendix S1). Meetings of the DSMB will take place
approximately every other month. In addition, an overview of serious
adverse events in the two studies will be sent to the chair of the DSMB
on a weekly basis.
Statistical considerations
Statistical methodology
There will be four analysis sets: the safety set (all patients who
have taken at least one dose of study drug and for whom data
following treatment are available); the full analysis set [all individuals
from the safety set with baseline and at least one post-baseline plasma
NT-proBNP value or who died or experienced permanent (≥5 consec-
utive days) withdrawal of study drug after cardiovascular hospitalization
or after emergency presentation for worsening chronic HF]; the per
protocol set (all patients from the full analysis set with valid plasma
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Table 1 Inclusion and exclusion criteria
Main inclusion criteria Main exclusion criteria
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Written informed consent signed before any study-specific procedure
Men and non-pregnant, non-lactating women aged ≥18 years
Women of childbearing potential must agree to use adequate
contraception (a combination of ≥2 effective methods of birth
control, of which ≥1 is a physical barrier)
Worsening chronic HF requiring emergency presentation to hospital
and treatment with IV diuretics at hospital
Treatment with ≥1 of the following for ≥3months before emergency
presentation to hospital: 𝛽-blocker, ACE inhibitor or ARB (not
both), MRA or diuretic
Medical history of LVEF ≤40% measured by any modality within the
last 12months without intervening revascularization or cardiac
surgery in the meantime; for individuals with cardiac intervention,
LVEF must be reassessed and a LVEF ≤40% must be reconfirmed
after the intervention
BNP concentration >400 pg/mL or plasma NT-proBNP concentration
>1200 pg/mL at any time during emergency presentation to
hospital, but at the latest at the screening visit
Patients with T2DM must fulfil ≥1 of the following:
• Receiving oral antidiabetics and/or insulin
• Documented fasting glucose concentration ≥7.0mmol/L in their
medical history
• Two-hour plasma glucose concentration ≥11.1mmol/L during an
OGTT
• Medical history of HbA1c concentration ≥6.5%*
and have an eGFR†≥30mL/min.1.73m2
Patients without T2DM must have an eGFR† of 30–60mL/min.1.73m2
at screening
Blood potassium concentration ≤5.0mmol/L at screening
Systolic blood pressure ≥90mmHg without signs or symptoms of
hypotension
Ability to understand and follow study-related instructions
Acute de novo HF or acute inflammatory heart disease
ACS‡ in the last 30 days before the screening visit
Cardiogenic shock
Valvular heart disease requiring surgical intervention during the
course of the study
Patients with a left ventricular assistance device or awaiting heart
transplantation
Stroke or TIA ≤3months before the screening visit
Known hypersensitivity to the study drug (active substance or
excipients) or eplerenone
Addison’s disease
Acute infectious disease requiring IV antibiotics within the last 24 h
before randomization
Dialysis for acute renal failure within the previous 3months before
emergency presentation to hospital
Hepatic insufficiency (Child–Pugh B or C)
Requirement for any IV vasodilator, any IV natriuretic peptide within
the 24 h before randomization, or any IV positive inotrope within
the 14 days before dosing with study drug
Treatment with either spironolactone or eplerenone that cannot be
discontinued 48 h or 24 h, respectively, before randomization and
for the duration of the treatment period
Treatment with any renin inhibitor or potassium-sparing diuretic that
cannot be discontinued 24 h before randomization and for the
duration of the treatment period
Treatment with high-dose ASA (>500mg/day) or another NSAID
Treatment with potent CYP3A4 inhibitors or inducers or strong
CYP2C8 inhibitors (all must be stopped ≥7 days before
randomization)
ACE, angiotensin converting enzyme; ACS, acute coronary syndromes; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; BNP, B-type natriuretic peptide; CKD,
chronic kidney disease; CYP, cytochrome P450; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HF, heart failure; IV, intravenous; LVEF, left ventricular
ejection fraction; MRA, mineralocorticoid receptor antagonist; NSAID, non-steroidal anti-inflammatory drug; NT-proBNP, N-terminal proBNP; OGTT, oral glucose tolerance
test; T2DM, type 2 diabetes mellitus; TIA, transient ischaemic attack.
*As defined in the National Glycohemoglobin Standardization Program or the Diabetes Control and Complications Trial.
†As measured using the Modification of Diet in Renal Disease equation.
‡As defined by the European Society of Cardiology40 and American College of Cardiology/American Heart Association41 guidelines.
NT-proBNP data at visit 7 or later and no major protocol deviations);
and the pharmacokinetic analysis set (all patients with at least one valid
finerenone plasma concentration measurement and without protocol
deviations that would interfere with evaluation of pharmacokinetic
data). In the full analysis set, patients who die or who experience
permanent withdrawal of study drug after cardiovascular hospitaliza-
tion or after emergency presentation for worsening chronic HF will
be considered as non-responders to avoid a bias towards treatment
responders in the assessment of the primary efficacy variable.
The primary efficacy variable, the percentage of patients with a
decrease in plasma NT-proBNP of more than 30% relative to baseline
at visit 9, will be assessed in the full analysis set (primary analysis) and
the per protocol set (supportive analysis).
Separate 𝜒2 tests with continuity correction will be applied to
compare each finerenone group with the eplerenone group. The
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.. Cochran–Mantel–Haenszel procedure will also be used to assess
finerenone vs. eplerenone stratified by region, comorbidities, and
MRA use at emergency presentation to hospital. Both tests will be
performed with a one-sided significance level of 5%. In cases where
the expected number of patients in at least one cell of a 2× 2
contingency table is less than 5, Fisher’s exact test will be used.
In the primary analysis, a last observation carried forward (LOCF)
method will be applied, whereby the highest plasma NT-proBNP value
from the premature discontinuation measurement and the follow-up
measurement will be used to impute missing plasma NT-proBNP
values at visit 9 for individuals who prematurely terminated the study.
Sensitivity analyses will be conducted.
These analyses will be repeated for the percentage of patients with
a decrease in plasma NT-proBNP of 50% or more relative to baseline
at visit 9 (without the LOCF imputation) and similar analyses will
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Additional treatment groups introduced
following a recommendation of the DSMB
Treatment groups
at study start
Initial stabilization
and screening
Randomization
15 mg o.d. finerenone
20 mg o.d. finerenone
20 mg o.d. finerenone
15 mg o.d. finerenone
10 mg o.d. finerenone
5 mg o.d. finerenone
10 mg o.d. finerenone
7.5 mg o.d. finerenone
2.5 mg o.d. finerenone
25 mg e.s.d. eplerenone
Acute/vulnerable phase
(days 1–30)
Up-titration if blood 
potassium ≤5.0 mmol/L
Up-titration/sham up-titration if 
blood potassium ≤5.0 mmol/L
Chronic phase (days 31–90)
25 mg o.d. eplerenone
50 mg o.d. eplerenone
5 mg o.d. finerenone
Safety follow-up
Figure 1 Study flow chart. The study enrols patients with chronic heart failure with reduced ejection fraction who also have type 2 diabetes
mellitus (T2DM) with chronic kidney disease (CKD), T2DM without CKD, or moderate CKD alone. DSMB, Data and Safety Monitoring Board;
e.s.d., every second day; o.d., once daily.
<5.6 mmol/L in local
AND central laboratories
>6.0 mmol/L in local
laboratory
>6.0 mmol/L in central
laboratory AND <5.6 mmol/L
in local laboratory
First [K+] measurement
>6.0 mmol/L in central
laboratory AND ≥5.6 mmol/L
in local laboratory
5.6–6.0 mmol/L in local 
OR central laboratory
Continue study drug Continue study drugRetest within 48 hours Permanently 
discontinue
study drug
Permanently 
discontinue
study drug
Permanently 
discontinue
study drug
<5.6 mmol/L in local
AND central laboratories
≥5.6 mmol/L in local 
OR central laboratory
Continue study drug
Second [K+] measurement
Figure 2 Monitoring of blood potassium concentration [K+] during the treatment period.
also be conducted for the decreases in plasma NT-proBNP relative
to baseline at visits 5 and 7. Absolute changes in plasma NT-proBNP
from baseline to visits 5, 7 and 9 will be assessed using separate analysis
of covariance (ANCOVA) models with the factors treatment group,
region, comorbidities, MRA use at emergency presentation to hospital,
AF and the baseline value as covariates. In cases where the data are
not approximately normally distributed, non-parametric methods or
transformation of the data will be applied.
Further exploratory efficacy variables will be analysed in the full
analysis and per protocol sets. Analyses of all safety variables will
be performed in the safety set. Changes in biomarkers from baseline ..
..
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..
. to visits 5, 7, and 9 and in HRQoL scores to visits 5 and 9 will be
investigated using separate ANCOVA models.
Time to cardiovascular hospitalization, emergency presentation for
worsening chronic HF, all-cause death, cardiovascular death and the
time to the first event of composites of these events will be esti-
mated based on the life-table and Kaplan–Meier methods. Differences
between each finerenone group and the eplerenone group will be
tested with the log-rank test.
The incidence of patients with a serum/plasma [K+] of 5.6mmol/L
or greater or more than 6.0mmol/L, or in different eGFR cate-
gories or categories of creatinine increase, will be investigated with
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Table 2 Schedule of assessment
Visit PD
visit
Follow-
up. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Screening 1 (BL) 2 (Dis)* 3 4† 5 6‡ 7 8§ 9
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Day ≤− 7 1 2–6 7± 2 14± 2 30± 2 37± 2 60± 2 67± 2 90± 2
Informed consent X
Demographic data X
Smoking history and alcohol X
Medical and surgical history X
Prior medications X
Local laboratory blood sample at screening X
Assess eligibility X X
Check height and weight X X X X X X X
Physical examination X X X X X
Vital signs X X X X X X X X X
12-lead ECG X X X X X X X X X
Adverse events X X X X X X X X X X X X
Concomitant medications X X X X X X X X X X X X
Randomization X
Dispense study drug X X X
Drug accountability, collect unused drug X X X X
Uptitration/sham uptitration of study drug X X
Local laboratory safety blood sample X X X X X X X X X
Central laboratory full blood sample X X X X X X
Blood and urine samples for biomarkers X X X X X X
Central laboratory blood sample for clinical chemistry X X X X X
Central laboratory blood sample for glycated haemoglobin X X X
Central laboratory single blood sample for PK X X
Central laboratory blood sample for PK¶ X
Central laboratory blood sample for PK|| X
HRQoL questionnaires X X X X X
Pregnancy test X
BL, baseline; Dis, discharge; ECG, electrocardiogram; HRQoL, health-related quality of life PD, premature discontinuation; PK, pharmacokinetic.
*Occurs on day of discharge from hospital only in those hospitalized at visit 1; visit 2 not performed with other patients.
†Occurs only in patients who are still in hospital at day 3; visit 4 not performed with other patients.
‡Occurs only for individuals up-titrated at visit 5.
§Only for individuals up-titrated at visit 7.
¶Study drug intake at home followed by two samples collected 60–120min and 240–300min post administration, respectively.
||Pre-dose PK sample at study centre followed by two samples collected 30–60min and 180–240min post-administration, respectively
frequency tables. Finerenone treatment groups will be compared with
the eplerenone group with respect to these incidences by 𝜒2 tests with
continuity correction. In addition, for these special safety parameters,
the absolute values and changes from baseline by treatment group will
be plotted vs. time. Furthermore, the frequency tables and summary
statistics will be repeated by treatment group and uptitration status
and separately for each of the stratification levels.
Pharmacokinetic data and HRQoL will be presented with descriptive
statistics. Absolute changes in HRQoL scores from baseline to visits 5
and 9 will be analysed using separate ANCOVA models.
Sample size
In ARTS (IMP 14563; NCT01345656), 37% of patients experienced
a greater than 30% decrease in plasma NT-proBNP from baseline
after 1month of treatment with finerenone 10mg once daily. Assum-
ing a time-constant effect, a greater than 30% decrease in plasma
NT-proBNP from baseline at visit 9 (day 90± 2) is expected in 37%
of patients treated with finerenone 5mg once daily with possible upti-
tration to 10mg once daily. No published reports on the proportion
of patients with particular percentage changes in plasma NT-proBNP
with eplerenone have been found. Therefore, this study is conducted
as an exploratory study: that is, no confirmatory testing on the primary
efficacy variable or other variables will be done. .
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. Assuming 37% as the primary efficacy result for finerenone and
21.4% for eplerenone, a sample size of 130 patients in the finerenone
group and 195 patients in the eplerenone group would result in a
power of 90% for a one-sided 𝜒2 test with continuity correction at
a significance level of 5%. Sample-size calculations were performed
with nQuery Advisor® 7.0 (Statistical Solutions, Cork, Ireland). Given
the size of these treatment groups, a total of 845 evaluable individuals
are needed. The screening failure rate is assumed to be approximately
30%, and 20% is added to allow for potential dilution of the treatment
effect owing to the inclusion of patients who die or discontinue the
study drug because of cardiovascular hospitalization or emergency
presentation for worsening chronic HF as non-responders in the
primary analysis. Considering these rates, approximately 1510 patients
will be screened.
Ethical considerations
The procedures set out in this protocol pertaining to the conduct,
evaluation and documentation of the study are designed to ensure
that the sponsor and investigators abide by Good Clinical Practice
guidelines and follow the guiding principles detailed in the Declaration
of Helsinki. The study will be carried out in keeping with applicable
local law(s) and regulation(s). Documented approvals from appropriate
independent ethics committee(s) or institutional review board(s) will
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be obtained for all participating centres/countries before the start of
the study.
Discussion
Finerenone is a next-generation non-steroidal MRA with greater
selectivity for the MR than spironolactone and stronger affinity for
the MR than eplerenone in vitro.18 Theoretically, a non-steroidal
MRA may possess a different ratio of end-organ protective activity
vs. undesirable epithelial electrolyte activity in comparison with the
available steroidal MRAs. This improved ratio could be achieved
by a combination of physicochemical properties that influence
plasma transport and tissue penetration, and different affinities
of the receptor–drug complex for tissue-specific co-factors.25
This theory is supported by two recent preclinical studies. Orena
et al.26 determined the plasma concentrations of eplerenone and
the novel non-steroidal MRA PF-03882845 that were necessary
to confer renal protection and to increase serum/plasma [K+] in
a rat kidney injury model. The authors determined a therapeutic
index (i.e. the ratio of EC50 for increasing serum/plasma [K+] to
the EC50 for reducing urine albumin levels) of PF-03882845 against
hyperkalaemia that was 57-fold superior to that of eplerenone.26
Similarly, Kolkhof et al.16 demonstrated that finerenone reduces
functional and structural parameters of end-organ failure more
efficiently than eplerenone at equinatriuretic doses in preclinical
rat disease models.
Data from the phase 2a ARTS study show that finerenone
2.5–10.0mg/day leads to significantly smaller increases in serum
[K+] and smaller decreases in eGFR than spironolactone 25mg
or 50mg once daily, with comparable efficacy, as measured by a
decrease in plasma NT-proBNP levels and albuminuria, in patients
with stable HFrEF and moderate CKD.19 Combined with the pre-
clinical data, these results suggest that finerenone could improve
outcomes in patients with HF, with a lower risk of hyperkalaemia
and worsening renal function than the steroidal MRAs, and should
be further investigated in other patient groups.
Although MRAs have not been previously systematically studied
in patients with worsening chronic HFrEF who require emergency
admission to hospital, evidence from the use of MRAs in other
patient groups and the finding that aldosterone and cortisol levels
are elevated in these patients suggest that the MR may be an
important therapeutic target in HFrEF. ARTS-HF is designed to
investigate the safety and potential efficacy of finerenone in a
dose range of 2.5–20mg/day in comparison to eplerenone in a
dose range 25mg every other day to 50mg/day in patients with
worsening chronic HFrEF and concomitant T2DM and/or CKD.
As doses of finerenone of 2.5–10mg once daily were tested in
ARTS, the same finerenone dose range was chosen for the initial
randomization groups for ARTS-HF. Following a recommendation
from the independent DSMB after review of ongoing data on the
safety and tolerability of finerenone, three pre-planned treatment
arms using higher doses of finerenone of up to 20mg once daily
were introduced.
The primary objective of ARTS-HF is to determine the doses
of finerenone that lead to larger proportions of patients who
have reductions in levels of plasma NT-proBNP of more than ..
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.. 30% relative to baseline, compared with eplerenone. It should be
noted that according to international guidelines4,5 the usefulness
of serial NT-proBNP measurements to improve clinical outcomes
in patients with HF is not well established. However, HF thera-
pies proven to have beneficial long-term effects on mortality, such
as ACE inhibitors, ARBs, 𝛽-blockers and cardiac resynchronization
therapy, tend to lead to a decrease in levels of natriuretic pep-
tide levels over time,27–31 and decreasing levels of plasma BNP
and NT-proBNP have also been observed during treatment with
steroidal MRAs.32–34 Although the ASTRONAUT (Aliskiren Trial
in Acute Heart Failure Outcomes) study of the effects of aliskiren
in hospitalized patients with HF showed decreases in NT-proBNP
that were not associated with improved clinical outcomes,35 sev-
eral other studies, including a sub-analysis of the 1742 patients
in the placebo arm of the Val-HeFT trial, have indicated that
intra-individual changes in plasma NT-proBNP concentrations are
a predictor of prognosis in patients with HF20–22 and that the
change in plasma NT-proBNP levels is a predictor of clinical
events. The percentage of patients with a relative decrease in
plasma NT-proBNP of more than 30% relative to baseline at
visit 9 (day 90± 2) as the primary efficacy variable was chosen
based on the results of prospective observational studies of the
prognostic relevance of changes in plasma NT-proBNP, which
showed that decreases of 30% or more correlate with improved
prognosis.22,36,37
While the primary endpoint can be considered as a surrogate
marker of efficacy, a key exploratory objective of this study is
to determine the effects of finerenone on a composite clinical
endpoint of death from any cause, cardiovascular hospitalizations,
or emergency presentations for worsening chronic HF. It was
considered appropriate to use this exploratory endpoint because
the rate of such events is expected to be high in the study
population and, given the results of preclinical rat studies described
above,16 a trend towards a more favourable change in this rate in
patients receiving finerenone than in those receiving eplerenone is
anticipated.
The RALES (Randomized Aldactone Evaluation Study) trial was
the first to demonstrate the efficacy of an MRA (spironolactone)
in the treatment of patients with severe chronic HFrEF.1 Since
the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and
Survival Study in Heart Failure) trial of eplerenone in patients with
less severe HFrEF was published in 2011,2 it has been recognized
that MRAs reduce mortality in this population; consequently,
future long-term studies investigating a new MRA in individuals
with HFrEF must use an active rather than a placebo control.
As a result of this consideration, eplerenone was chosen as the
comparator in ARTS-HF. Evidence from several studies suggests
that eplerenone may be more suitable than spironolactone in
patients with chronic HF and T2DM because of the metabolic
effects of spironolactone, particularly on glycated haemoglobin.38,39
Furthermore, spironolactone is thought to be associated with
a higher incidence of hyperkalaemia than eplerenone in patients
with CKD because of its longer serum half-life. Given that the
proportion of CKD in our study population of patients with
worsening chronic HFrEF is expected to be high, the starting dose
of eplerenone chosen, 25mg every second day, is in line with
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the recommended starting dose of eplerenone in patients with an
eGFR of 30–60mL/min.1.73m2 in stable HFrEF patients.
In addition to assessing the safety and potential efficacy of
finerenone in patients with worsening chronic HFrEF, ARTS-HF
will provide information on its effects on HRQoL as well as
its pharmacokinetic properties and its optimal dosing in these
patients.
Conclusion
ARTS-HF is a multicentre, randomized, double-blind,
active-comparator-controlled, parallel-group phase 2b dose-finding
study. It has been designed to assess the potential efficacy and
safety of different doses of the non-steroidal MRA finerenone
compared with eplerenone in patients with worsening chronic HF
and concomitant T2DM and/or CKD presenting to the emergency
department. Should our hypothesis prove correct that finerenone
treatment has the potential to reduce serum levels of markers of
HF and improve predefined clinical outcomes in these patients,
with an acceptable safety profile, this study could open the door
to larger clinical outcomes studies in this patient group.
Supplementary Information
Additional Supporting Information may be found in the online
version of this article:
Appendix S1. DSMB members
Figure S1. Timeline of the visits and main procedures of the
MinerAlocorticoid Receptor antagonist Tolerability Study-Heart
Failure (ARTS-HF).
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